Skip to main content
SpringerLink
Log in

Introduction

  • Chapter
  • First Online:
Management of Castration Resistant Prostate Cancer

Part of the book series: Current Clinical Urology ((CCU))

  • 836 Accesses

Abstract

In the last years unprecedented progress has been made with drug development in castration-resistant metastatic prostate cancer and that have (mCRPC) with six drugs that have other compounds are in late stages shown to significantly prolong survival and that have been approved and several more in late stages of development. However, at the same time combination strategies namely with docetaxel-chemotherapy have all failed in large Phase III randomized trials. In the following introduction challenges and pitfalls of drug development in CRPC will be discussed.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Jemal A, Siegel R, et al. Cancer statistics, 2010. CA Cancer J Clin. 2010;60(5):277–300.

    Google Scholar 

  2. Berthold DR, Pond GR, et al. Treatment of hormone-refractory prostate cancer with docetaxel or mitoxantrone: relationships between prostate-specific antigen, pain, and quality of life response and survival in the TAX-327 study. Clin Cancer Res. 2008;14(9):2763–7.

    Google Scholar 

  3. Tannock IF, de Wit R, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351(15):1502–12.

    Article  CAS  PubMed  Google Scholar 

  4. de Bono JS, Oudard S, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010;376(9747):1147–54.

    Article  PubMed  Google Scholar 

  5. de Bono JS, Logothetis CJ, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364(21):1995–2005.

    Article  PubMed Central  PubMed  Google Scholar 

  6. Ryan CJ, Smith MR, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2013;368(2):138–48.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  7. Scher HI, Fizazi K, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367(13):1187–97.

    Article  CAS  PubMed  Google Scholar 

  8. Attard G, Reid AH, et al. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol. 2009;27(23):3742–8.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  9. Attard G, Reid AH, et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol. 2008;26(28):4563–71.

    Article  CAS  PubMed  Google Scholar 

  10. Scher HI, Beer TM, et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study. Lancet. 2010;375(9724):1437–46.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  11. Higano CS, Schellhammer PF, et al. Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer. 2009;115(16):3670–9.

    Article  CAS  PubMed  Google Scholar 

  12. Kantoff PW, Higano CS, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363(5):411–22.

    Article  CAS  PubMed  Google Scholar 

  13. Huber ML, Haynes L, et al. Interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer. J Natl Cancer Inst. 2012;104(4):273–9.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  14. Nilsson S, Franzen L, et al. Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study. Lancet Oncol. 2007;8(7):587–94.

    Article  CAS  PubMed  Google Scholar 

  15. Parker C, Nilsson S, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369(3):213–23.

    Article  CAS  PubMed  Google Scholar 

  16. Sharma MR, Stadler WM, et al. Randomized phase II trials: a long-term investment with promising returns. J Natl Cancer Inst. 2011;103(14):1093–100.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  17. Krzyzanowska MK, Pintilie M, et al. Factors associated with failure to publish large randomized trials presented at an oncology meeting. JAMA. 2003;290(4):495–501.

    Article  PubMed  Google Scholar 

  18. Galsky MD, Vogelzang NJ. Docetaxel-based combination therapy for castration-resistant prostate cancer. Ann Oncol. 2010;21(11):2135–44.

    Article  CAS  PubMed  Google Scholar 

  19. Di Lorenzo G, Figg WD, et al. Combination of bevacizumab and docetaxel in docetaxel-pretreated hormone-refractory prostate cancer: a phase 2 study. Eur Urol. 2008;54(5):1089–94.

    Article  PubMed  Google Scholar 

  20. Kelly WK, Halabi S, et al. Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401. J Clin Oncol. 2012;30(13):1534–40.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  21. Isambert N, Freyer G, et al. Phase I dose-escalation study of intravenous aflibercept in combination with docetaxel in patients with advanced solid tumors. Clin Cancer Res. 2012;18(6):1743–50.

    Article  CAS  PubMed  Google Scholar 

  22. Coleman RL, Duska LR, et al. Phase 1-2 study of docetaxel plus aflibercept in patients with recurrent ovarian, primary peritoneal, or fallopian tube cancer. Lancet Oncol. 2011;12(12):1109–17.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  23. Tannock I, Fizazi K, et al. Double-blind randomized trial of aflibercept versus placebo with docetaxel and prednisone for treatment of metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol. 2013;31 (suppl; abstr 5002).

    Google Scholar 

  24. Armstrong AJ, Creel P, et al. A phase I-II study of docetaxel and atrasentan in men with castration-resistant metastatic prostate cancer. Clin Cancer Res. 2008;14(19):6270–6.

    Article  CAS  PubMed  Google Scholar 

  25. Quinn DI, Tangen CM, et al. Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial. Lancet Oncol. 2013;14(9):893–900.

    Article  CAS  PubMed  Google Scholar 

  26. Carducci MA, Saad F, et al. A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer. Cancer. 2007;110(9):1959–66.

    Article  CAS  PubMed  Google Scholar 

  27. Trump DL, Payne H, et al. Preliminary study of the specific endothelin a receptor antagonist zibotentan in combination with docetaxel in patients with metastatic castration-resistant prostate cancer. Prostate. 2011;71(12):1264–75.

    CAS  PubMed  Google Scholar 

  28. Fizazi KS, Higano CS, et al. Phase III, randomized, placebo-controlled study of docetaxel in combination with zibotentan in patients with metastatic castration-resistant prostate cancer. J Clin Oncol. 2013;31(14):1740–7.

    Article  CAS  PubMed  Google Scholar 

  29. Araujo JC, Mathew P, et al. Dasatinib combined with docetaxel for castration-resistant prostate cancer: results from a phase 1-2 study. Cancer. 2012;118(1):63–71.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  30. Araujo JC, Trudel GC, et al. Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial. Lancet Oncol. 2013;14(13):1307–16.

    Article  CAS  PubMed  Google Scholar 

  31. Higano CS, Corman JM, et al. Phase 1/2 dose-escalation study of a GM-CSF-secreting, allogeneic, cellular immunotherapy for metastatic hormone-refractory prostate cancer. Cancer. 2008;113(5):975–84.

    Article  CAS  PubMed  Google Scholar 

  32. Small E, Demkow T, et al. A phase III trial of GVAX immunotherapy for prostate cancer in combination with docetaxel versus docetaxel plus prednisone in symptomatic, castration-resistant prostate cancer (CRPC). In: JCO 2009 Genitourinary Cancers Symposium. 2009; Abstract 07.

    Google Scholar 

  33. Petrylak DP, Fizazi K, et al. A phase 3 study to evaluate the efficacy and safety of docetaxel and prednisone (DP) with or without lenalidomide (LEN) in patients with castrate-resistant prostate cancer (CRPC): the MAINSAIL trial. Ann Oncol. 2012 (suppl 9); abstract 2462.

    Google Scholar 

  34. Petrylak DP, Resto-Garces K, et al. A phase I open-label study using lenalidomide and docetaxel in castration- resistant prostate cancer. J Clin Oncol. 2009;27:15s (suppl; abstr 5156).

    Google Scholar 

  35. Beer TM, Eilers KM, et al. Weekly high-dose calcitriol and docetaxel in metastatic androgen-independent prostate cancer. J Clin Oncol. 2003;21(1):123–8.

    Article  CAS  PubMed  Google Scholar 

  36. Beer TM, Ryan CW, et al. Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT investigators. J Clin Oncol. 2007;25(6):669–74.

    Article  CAS  PubMed  Google Scholar 

  37. Scher HI, Jia X, et al. Randomized, open-label phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancer. J Clin Oncol. 2011;29(16):2191–8.

    Article  CAS  PubMed  Google Scholar 

  38. Chi KN, Zoubeidi A, et al. Custirsen (OGX-011): a second-generation antisense inhibitor of clusterin for the treatment of cancer. Expert Opin Investig Drugs. 2008;17(12):1955–62.

    Article  CAS  PubMed  Google Scholar 

  39. James ND, Pirrie S, et al. Clinical outcomes in patients with castrate-refractory prostate cancer (CRPC) metastatic to bone randomized in the factorial TRAPEZE trial to docetaxel (D) with strontium-89 (Sr89), zoledronic acid (ZA), neither, or both (ISRCTN 12808747). J Clin Oncol. 2013;31 (suppl; abstr LBA5000).

    Google Scholar 

  40. Antonarakis ES, Eisenberger MA. Phase III trials with docetaxel-based combinations for metastatic castration-resistant prostate cancer: time to learn from past experiences. J Clin Oncol. 2013;31(14):1709–12.

    Article  CAS  PubMed  Google Scholar 

  41. Prentice RL. Surrogate endpoints in clinical trials: definition and operational criteria. Stat Med. 1989;8(4):431–40.

    Article  CAS  PubMed  Google Scholar 

  42. de Bono JS, Scher HI, et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res. 2008;14(19):6302–9.

    Article  PubMed  Google Scholar 

  43. Scher HI, Heller G, et al. Evaluation of a composite biomarker panel including circulating tumor cell (CTC) enumeration as a surrogate for survival in metastatic castration-resistant prostate cancer (mCRPC). In: The European cancer congress 2013, Abstract 2851; 2013.

    Google Scholar 

  44. Armstrong AJ, Eisenberger MA, et al. Biomarkers in the management and treatment of men with metastatic castration-resistant prostate cancer. Eur Urol. 2012;61(3):549–59.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  45. Armstrong AJ, Garrett-Mayer E, et al. Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer. J Clin Oncol. 2007;25(25):3965–70.

    Article  PubMed  Google Scholar 

  46. Armstrong AJ, Garrett-Mayer ES, et al. A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis. Clin Cancer Res. 2007;13(21):6396–403.

    Article  CAS  PubMed  Google Scholar 

  47. Halabi S, Small EJ, et al. Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol. 2003;21(7):1232–7.

    Article  PubMed  Google Scholar 

  48. Smaletz O, Scher HI, et al. Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration. J Clin Oncol. 2002;20(19):3972–82.

    Article  PubMed  Google Scholar 

  49. Omlin A, Pezaro C, et al. Improved survival in a cohort of trial participants with metastatic castration-resistant prostate cancer demonstrates the need for updated prognostic nomograms. Eur Urol. 2013;64:300–6.

    Article  PubMed  Google Scholar 

  50. Speight J, Barendse SM. FDA guidance on patient reported outcomes. BMJ. 2010;340:c2921.

    Article  PubMed  Google Scholar 

  51. Basch E, Abernethy AP, et al. Recommendations for incorporating patient-reported outcomes into clinical comparative effectiveness research in adult oncology. J Clin Oncol. 2012;30(34):4249–55.

    Article  PubMed  Google Scholar 

  52. Basch E. Toward patient-centered drug development in oncology. N Engl J Med. 2013;369(5):397–400.

    Article  CAS  PubMed  Google Scholar 

  53. Aaronson NK, Ahmedzai S, et al. The European organization for research and treatment of cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85(5):365–76.

    Article  CAS  PubMed  Google Scholar 

  54. Esper P, Mo F, et al. Measuring quality of life in men with prostate cancer using the functional assessment of cancer therapy-prostate instrument. Urology. 1997;50(6):920–8.

    Article  CAS  PubMed  Google Scholar 

  55. Chi KN, Kheoh TS, et al. A prognostic model for predicting overall survival (OS) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone acetate (AA) after docetaxel. J Clin Oncol. 2013;31(suppl; abstr 5013).

    Google Scholar 

  56. Halabi S, Armstrong AJ, et al. Prostate-specific antigen decline (PSA) as a surrogate for overall survival (OS) in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC) who failed first-line chemotherapy. J Clin Oncol. 2012;30(suppl; abstr 4515).

    Google Scholar 

  57. Hirano D, Okada Y, et al. Neuroendocrine differentiation in hormone refractory prostate cancer following androgen deprivation therapy. Eur Urol. 2004;45(5):586–92. discussion 592.

    Article  CAS  PubMed  Google Scholar 

  58. Keizman D, Gottfried M, et al. Pretreatment neutrophil-to-lymphocyte ratio in metastatic castration-resistant prostate cancer patients treated with ketoconazole: association with outcome and predictive nomogram. Oncologist. 2012;17(12):1508–14.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Royal Marsden NHS Foundation Trust, Section of Medicine, Sycamore House, Downs Road, Sutton, Surrey, SM2 5PT, UK

    Aurelius Omlin MD

  2. Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Prostate Cancer Targeted Therapy Group, Sutton, UK

    Carmel Pezaro MBChB, DMedSc, FRACP

  3. The Royal Marsden HNS Foundation Trust, Drug Development Unit, Sycamore House, Downs Road, Sutton, Surrey, SM2 5PT, UK

    Johann S. de Bono MBChB, FRCP, MSc, PhD

Authors
  1. Aurelius Omlin MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Carmel Pezaro MBChB, DMedSc, FRACP
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Johann S. de Bono MBChB, FRCP, MSc, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Johann S. de Bono MBChB, FRCP, MSc, PhD .

Editor information

Editors and Affiliations

  1. Department of Surgery, University of Montreal Hospital Center, Montreal, Québec, Canada

    Fred Saad

  2. Department of Oncology, The Johns Hopkins University, Baltimore, Maryland, USA

    Mario A. Eisenberger

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer Science+Business Media New York

About this chapter

Cite this chapter

Omlin, A., Pezaro, C., de Bono, J.S. (2014). Introduction. In: Saad, F., Eisenberger, M. (eds) Management of Castration Resistant Prostate Cancer. Current Clinical Urology. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-1176-9_12

Download citation

  • DOI: https://doi.org/10.1007/978-1-4939-1176-9_12

  • Published:

  • Publisher Name: Humana Press, New York, NY

  • Print ISBN: 978-1-4939-1175-2

  • Online ISBN: 978-1-4939-1176-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation